Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Titel:
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Auteur:
Saura, Cristina Hlauschek, Dominik Oliveira, Mafalda Zardavas, Dimitrios Jallitsch-Halper, Anita de la Peña, Lorena Nuciforo, Paolo Ballestrero, Alberto Dubsky, Peter Lombard, Janine M Vuylsteke, Peter Castaneda, Carlos A Colleoni, Marco Santos Borges, Giuliano Ciruelos, Eva Fornier, Monica Boer, Katalin Bardia, Aditya Wilson, Timothy R Stout, Thomas J Hsu, Jerry Y Shi, Yi Piccart, Martine Gnant, Michael Baselga, José de Azambuja, Evandro